- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
Jeffrey Wolf, MD | Authors
Jeffrey Wolf, MD, on Emerging T-Cell Engagers and Their Impact in Multiple Myeloma
January 09, 2021
The interview features comments on the emergence of T-cell engagers for therapy in patients with multiple myeloma made during the 2020 ASH Meeting & Exposition.
Jeffrey Wolf, MD, on the Lack of MRD Results at ASH and the Future of Myeloma Trials
January 05, 2021
Jeffrey Wolf, MD, explained how studies presented at the recent 2020 ASH Annual Meeting & Exposition did not report what percentage of patients achieved minimal residual disease negativity with therapy for multiple myeloma, and that the future of phase 3 trials should focus on this status in patients.
Jeffrey Wolf, MD, on the Future of MRD and More Sensitive Measuring Techniques in Myeloma
January 01, 2021
Wolf touched on the future of MRD and the potential development of more sensitive measuring techniques for patients with multiple myeloma.
Jeffrey Wolf, MD, on Implications of Findings from Multiple Myeloma Study Presented at ASH
December 27, 2020
Wolf touched on the implications of results from a study investigating outcomes when making clinical decisions based on the MRD status of patients with multiple myeloma.
Jeffrey Wolf, MD, on Findings From a Study Investigating Therapy Changes Using MRD in Patients With Multiple Myeloma
December 19, 2020
Wolf discussed the decisions to change therapy based on the MRD status of patients with multiple myeloma.
Jeffrey Wolf, MD, on Next-Generation CAR T Cell Therapy and the Future of Multiple Myeloma Treatments
December 11, 2020
Wolf discusses the potential for emerging next-generation CAR T-cell treatment and the future of treating patients with multiple myeloma.